| 1 |
34894960 | Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. | 2022 Feb |
1 |
| 2 |
35093904 | Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" study). | 2022 Feb |
1 |
| 3 |
33785482 | Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). | 2021 Jun 15 |
2 |
| 4 |
34196874 | Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. | 2021 Sep |
2 |
| 5 |
31618131 | Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. | 2020 Apr 20 |
1 |
| 6 |
31773503 | Everolimus-associated cytomegalovirus colitis in a patient with metastasized breast cancer: a case report. | 2020 Jul |
1 |
| 7 |
31841262 | High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. | 2020 Mar |
1 |
| 8 |
31932237 | A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. | 2020 Apr |
1 |
| 9 |
32043762 | Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. | 2020 Feb |
1 |
| 10 |
32062536 | Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. | 2020 Apr |
1 |
| 11 |
32170637 | Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. | 2020 Oct |
1 |
| 12 |
32252811 | Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. | 2020 Apr 6 |
1 |
| 13 |
32566979 | PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane. | 2020 Nov |
2 |
| 14 |
33182575 | Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. | 2020 Nov 10 |
2 |
| 15 |
29992557 | Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. | 2019 Feb 15 |
1 |
| 16 |
30515367 | The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. | 2019 Feb |
1 |
| 17 |
30610588 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. | 2019 Apr |
4 |
| 18 |
30679318 | Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. | 2019 Jul |
2 |
| 19 |
30798641 | Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. | 2019 Mar |
1 |
| 20 |
31036468 | Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2019 Jun |
1 |
| 21 |
31594912 | Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. | 2019 Oct 8 |
1 |
| 22 |
29097108 | Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial. | 2018 Apr |
2 |
| 23 |
29116433 | Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain. | 2018 Jun |
1 |
| 24 |
29124456 | Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. | 2018 Feb |
1 |
| 25 |
29520681 | Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer. | 2018 Mar 8 |
3 |
| 26 |
30155246 | Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety. | 2018 Sep |
2 |
| 27 |
28789401 | Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. | 2017 Aug |
1 |
| 28 |
26503204 | Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. | 2016 Feb 10 |
1 |
| 29 |
27044936 | Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. | 2016 Jul 1 |
1 |
| 30 |
27733047 | Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series. | 2016 Nov |
1 |
| 31 |
28101033 | Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin. | 2016 Sep-Dec |
1 |
| 32 |
26493064 | Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. | 2015 Nov |
1 |
| 33 |
24362951 | Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. | 2014 Feb |
1 |
| 34 |
24691195 | [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option]. | 2014 Mar |
1 |
| 35 |
24833916 | Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. | 2014 |
1 |
| 36 |
27202256 | Cost Effectiveness Analysis of Everolimus + Exemestane for Patients with Advanced Breast Cancer with Positive Estrogen Receptor (ER +), HER2-, Refractory to Non-Steroidal Aromatase Inhibitors (NSAIS) in Chile. | 2014 Nov |
1 |
| 37 |
23529824 | Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. | 2013 Apr |
1 |